Goat or Cow Milk Based Infant Formula GMS

Description

This study is a non-inferiority, decentralized, randomized, double-blind, controlled clinical trial evaluating the growth, tolerance, and safety of a goat's-milk test infant formula (Test Formula 1; TF1) and a cow's-milk test infant formula (Test Formula 2; TF2), each compared to a cow's-milk infant formula commercially available in the United States (Control Formula; CF).

Conditions

Growth

Study Overview

Study Details

Study overview

This study is a non-inferiority, decentralized, randomized, double-blind, controlled clinical trial evaluating the growth, tolerance, and safety of a goat's-milk test infant formula (Test Formula 1; TF1) and a cow's-milk test infant formula (Test Formula 2; TF2), each compared to a cow's-milk infant formula commercially available in the United States (Control Formula; CF).

Growth Tolerance and Safety Study of Healthy Term Infants Consuming a Goat or Cow Milk Based Infant Formula

Goat or Cow Milk Based Infant Formula GMS

Condition
Growth
Intervention / Treatment

-

Contacts and Locations

New York

ObvioHealth USA, Inc., New York, New York, United States, 10001

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Healthy term infants (37 to 42 weeks gestation at birth) from a singleton birth as assessed by the investigator
  • 2. Infants with a birth weight of \>2500 g to \<4500 g
  • 3. Infants ≤11 days of age at enrollment; birth constitutes Day 0
  • 4. Parent/legal guardian who has previously decided to exclusively feed infant formula and is willing to continue with formula feeding throughout the study
  • 1. Infant born with medical complications (e.g., neurological, cerebral palsy, etc.)
  • 2. Infant with failure to thrive, fever, any GI tract abnormalities (e.g., short gut, gastroesophageal reflux, etc.), any congenital illness or malformation that may affect infant feeding or normal growth
  • 3. Infant has been treated with prescription medications that in the Investigator's opinion could impact growth, gastrointestinal tolerance and/or development
  • 4. Infant that has received oral or parenteral antibiotics prior to enrollment
  • 5. Infant is taking and parent/legal guardian plans to continue (including over-the-counter medications, such as Mylicon® for gas), home remedies (such as juice for constipation), gastroesophageal reflux medications, herbal preparations, or rehydration fluids that, in the Investigator's opinion, might affect gastrointestinal tolerance. Use of the following are strongly discouraged for the duration of the trial:
  • 1. Solid foods and juices
  • 2. Vitamins and/mineral supplements, as the study product provided is nutritionally complete
  • 3. Pre- and probiotics
  • 6. Infant with family history (biological siblings or parents) of confirmed milk protein allergy (Parent's lactose intolerance is not disqualifying)
  • 7. Parent(s)/Legal guardian(s) intent on feeding non-study formula, breastmilk, juices, or solid food during the study.

Ages Eligible for Study

to 14 Days

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Kendal Nutricare Ltd,

Allan Soo, PRINCIPAL_INVESTIGATOR, MD, FAPCR ObvioHealth USA, Inc.

Study Record Dates

2024-08-15